Press release

Medios AG enters market for medicinal cannabis

• Expansion of product portfolio with medicinal cannabis
• Medios obtains exclusive distribution rights for Bedrocan® products in agreed European markets
• Entry into an attractive growth market and strengthening expertise in existing indication areas

Berlin, January 19, 2026 – The Medios Group (“Medios” or “the Company”), a leading Specialty Pharma provider in Europe, is expanding its product portfolio and entering the medicinal cannabis market. To this end, Medios is partnering with the Dutch company Bedrocan International B.V. (“Bedrocan”), a leading international manufacturer of pharmaceutical-grade cannabis. Medios secures exclusive distribution rights for Bedrocan products in Germany, Spain, Belgium, Italy, and Austria. The agreement initially covers medicinal cannabis from Bedrocan’s EU-GMP^[1]-certified Danish facility and will expand to include products from other Bedrocan production sites as of January 1, 2027.

The partnership has already been established with a focus on the German market and will be gradually expanded to additional EU countries over the next two years. It builds on Medios extensive footprint in the German and EU pharmacy market and many years of experience in GDP^[2]-certified pharmaceutical logistics. Cannaflos, “Gesellschaft für medizinisches Cannabis mbH”, will support Medios as a distribution partner in Germany.

Constantijn van Rietschoten, Member of the Executive Board of Medios AG: “By entering the medicinal cannabis market, we are expanding our portfolio to include a product that can play an important role for numerous patients with chronic and serious diseases. Especially in the fields of oncology and neurology, cannabis offers a valuable addition to the therapy.”

Strategic importance for Medios
Medicinal cannabis is currently used, among other things, to relieve pain, nausea and loss of appetite in patients, for example, in the context of oncological therapies. With the expansion of the product portfolio, Medios is specifically strengthening its expertise in oncology and neurology as well as in other indication areas where supportive treatments are required. The move underlines Medios’ positioning as a comprehensive partner for patient-specific therapies.

Market dynamics
In Germany, an increasing number of patients are benefiting from access to medicinal cannabis. Medios is specifically targeting the segment of reimbursable medicinal cannabis, ensuring independence from potential legislative changes affecting the self-payer market. As a pioneer in this market, Bedrocan has established a trusted and strong position, with many patients relying on the consistent availability of high-quality medicinal cannabis. With its entry into the market of reimbursable medicinal cannabis and its strategic partnership with Bedrocan, Medios is positioning itself as a key player in this important and growing field in Germany.

Important events for Medios AG in the 2026 financial year:

——————-

About Bedrocan
Bedrocan is the leading producer of medicinal cannabis of pharmaceutical quality. For over 20 years, Bedrocan has specialised in the production of cannabis as an Active Pharmaceutical Ingredient (API) in accordance with EU-GMP standards. Bedrocan focuses on delivering medicinal cannabis with a consistent cannabinoid profile, adhering to defined pharmaceutical specifications. This commitment to consistency and reliability supports a trusted and reproducible therapy for patients. Bedrocan supplies authorities and partners in numerous countries and makes a significant contribution to the professionalization of the medicinal cannabis market with its science-based approach.

About Medios AG
Medios is a leading provider of specialty pharmaceuticals in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios focuses on future-oriented individual medicine to enable all people to receive the most innovative therapies together with pharmacies, specialist practices, and pharmaceutical companies.

Medios AG is Germany’s first listed specialty pharmaceutical company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) and are listed in the SDAX selection index.

www.medios.group

More information on the topic of individual medicine: https://app.medios.group/individualmedizin

Contact
Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
ir@medios.group
www.medios.group

Disclaimer

This release contains forward-looking statements that are subject to certain risks and uncertainties. Future results may differ materially from those currently anticipated due to various risk factors and uncertainties, such as changes in business, economic and competitive conditions, exchange rate fluctuations, uncertainties regarding litigation or investigations, and the availability of funds. Medios AG assumes no responsibility to update the forward-looking statements contained in this release.

^[1] Good Manufacturing Practice

^[2] Good Distribution Practice